Cardiac Electrophysiology, Electrocardiography (ECG), Estradiol, In Vitro Fertilization, Reproductive Endocrinology
Conditions
Brief summary
This prospective observational study aimed to evaluate the effects of supraphysiological estradiol (E2) levels, induced by gonadotropin therapy during IVF, on cardiac electrophysiological parameters. Sixty-two women aged 18-40 undergoing IVF treatment at Konya City Hospital between December 2024 and January 2025 were included. ECG recordings were performed twice: once before gonadotropin stimulation and again on the day of hCG administration, when peak E2 levels were expected. Routine blood tests and hormone levels were also evaluated. Patients with obesity, cardiovascular disease, chronic illness, or medication use were excluded. After treatment, significant increases were observed in PR interval, J-Tpeak, QTc, and Tp-e values. E2 changes showed a moderate negative correlation with QTc and a low positive correlation with J-Tpeak. The results suggest that elevated E2 levels during IVF may affect cardiac electrophysiology, highlighting the need for careful monitoring in women with cardiac risk factors.
Interventions
None listed
Sponsors
Konya City Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Inclusion criteria
* Female patients aged 18 to 40 years Undergoing IVF treatment at Konya City Hospital between December 2024 and January 2025 No cardiac pathology based on cardiology consultation Eligible for controlled ovarian stimulation using a short antagonist protocol Provided informed consent
Exclusion criteria
\- Age under 18 or over 40 years Baseline estradiol level \> 50 ng/L on day 2 of menstrual cycle Presence of any known chronic diseases (e.g., diabetes mellitus, hypertension, rheumatologic disorders, thyroid disorders) Use of any medications other than those used for IVF Current smoker or alcohol user Family history of cardiac disease or sudden cardiac death Personal history of myocardial infarction, angina, heart failure, or any structural heart disease History of cardiac surgery or coronary intervention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in QTc Interval Before and After Gonadotropin-Induced Estradiol Elevation | Approximately 8-12 days from baseline to post-treatment ECG | QTc interval will be measured via 12-lead electrocardiography (ECG) at two timepoints: (1) on menstrual cycle day 2-3 prior to gonadotropin stimulation (baseline), and (2) on the day of hCG administration when estradiol reaches peak levels. The difference between pre- and post-treatment QTc values will be calculated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in PR Interval Following Gonadotropin-Induced Estradiol Elevation | Approximately 8-12 days | PR interval will be assessed using standard 12-lead ECG both before and after gonadotropin stimulation. Measurements will be taken on menstrual day 2-3 and again on the day of hCG administration to evaluate PR interval prolongation in response to elevated estradiol levels. |
Countries
Turkey (Türkiye)
Outcome results
None listed